Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meditech

This article was originally published in The Tan Sheet

Executive Summary

Clinical trials comparing Zorex topical cold sore formula against two competitive products will be conducted by Boston University, Scottsdale, Ariz.-based firm announces. Clinicals are expected to last six months; if successful, results will be used to support advertising, marketing claims for Zorex, which contains monographed ingredient for pain, cold sore symptoms, as well as MTCH-24 compound. Meditech delaying regional launch of Zorex pending negotiations with five pharmaceutical companies (1"The Tan Sheet" April 2, In Brief)

You may also be interested in...



Meditech

Firm plans to use proceeds from stock offering to regionally launch and market an OTC cold sore treatment by August, with a national rollout planned for January 2002. Zorex will contain a monographed ingredient for pain and symptoms of cold sores, as well as Scottsdale, Ariz.-based Meditech's MTCH-24 compound. Company also will use funds from sale of up to 73 mil. shares to complete clinical trials supporting an NDA for MTCH-24 as an OTC active for treatment of cold sores. Meditech is in talks with several pharma companies regarding licensing rights for Rx and OTC drugs containing MTCH-24. Results of company-funded study on Zorex's efficacy in treating herpes simplex will be presented at International Conference on Antiviral Research in Seattle April 10

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS092655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel